Scholars@Duke
Thomas Lawrence Holland

Thomas Lawrence Holland

Professor of Medicine
Medicine, Infectious Diseases
Duke Box 102359, Durham, NC 27710
Room 163 Hanes House, Trent Drive, Durham, NC 27710

Current Appointments & Affiliations

Professor of Medicine · 2024 - Present Medicine, Infectious Diseases, Medicine
Membership in the Duke Clinical Research Institute · 2015 - Present Duke Clinical Research Institute, Institutes and Centers

In the News

Published October 4, 2023
Drug Found Effective in Fighting Deadly Infections
Published July 11, 2022
Monoclonal Antibody Treatment Reduced Deaths in Hospitalized COVID Patients
Published September 26, 2018
New Way of Determining Treatment for Staph Infections Cuts Antibiotic Use

View All News

Recent Publications

Management of Staphylococcus aureus Bacteremia: A Review.

Journal Article JAMA · September 2, 2025 IMPORTANCE: Staphylococcus aureus, a gram-positive bacterium, is the leading cause of death from bacteremia worldwide, with a case fatality rate of 15% to 30% and an estimated 300 000 deaths per year. OBSERVATIONS: Staphylococcus aureus bacteremia causes m ... Full text Link to item Cite

Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial.

Journal Article JAMA · August 13, 2025 IMPORTANCE: Dalbavancin is a long-acting intravenous lipoglycopeptide that may be effective for treatment of complicated Staphylococcus aureus bacteremia without requiring long-term intravenous access. OBJECTIVE: To evaluate the efficacy and safety of dalb ... Full text Link to item Cite

A Qualitative Secondary Analysis of Patient Health-Related Quality of Life in Bloodstream Infections by Source: Intra-abdominal, Urinary Tract, and Acute Bacterial Skin and Skin Structure Infection.

Journal Article Clin Infect Dis · August 6, 2025 BACKGROUND: Despite the prevalence of intra-abdominal infections, urinary tract infections, and skin/skin structure infections, the relative impact of these syndromes on patient health-related quality of life (HRQoL) is unclear. This qualitative secondary ... Full text Link to item Cite
View All Publications

Recent Grants

Invasive Candidiasis

Clinical TrialPrincipal Investigator · Awarded by Basilea Pharmaceutica · 2024 - 2028

Antibacterial Resistance Leadership Group (ARLG)

ResearchCo Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2013 - 2026

HR-BV 3

Clinical TrialPrincipal Investigator · Awarded by Biomeme, Inc. · 2023 - 2024

View All Grants

Education, Training & Certifications

Wake Forest University · 2005 M.D.